Mig Dla Dzieci (Ibuprofen)

Ibuprofen, the active ingredient in Mig Dla Dzieci, is a nonsteroidal anti‑inflammatory drug presented as an oral formulation for oral use. It is used to relieve pain, reduce fever, and lessen inflammation, particularly in pediatric patients.

GNH USA supplies Mig Dla Dzieci as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Ibuprofen is a nonsteroidal anti‑inflammatory drug that reduces pain, fever and inflammation in children. - Pain: provides relief from mild to moderate discomfort such as headache, toothache or muscle aches. - Fever: lowers elevated body temperature associated with viral or bacterial infections. - Inflammation: decreases swelling and redness in conditions like minor injuries or sprains.

Common Side Effects: - Stomach upset or dyspepsia - Nausea or vomiting - Headache - Dizziness - Mild skin rash - Diarrhea

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulceration - Severe allergic reactions (anaphylaxis, angioedema) - Kidney impairment or acute renal failure - Liver enzyme elevation or hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood disorders such as thrombocytopenia

Before using Mig Dla Dzieci, consider the following safety measures: - Assess renal function: avoid or adjust use in patients with significant kidney disease. - Monitor gastrointestinal risk: contraindicated in active peptic ulcer disease or history of severe GI bleeding. - Avoid concurrent NSAIDs: combined use increases bleeding and ulcer risk. - Use with caution in asthma: may precipitate bronchospasm in susceptible children. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ibuprofen may interact with several medicines; review the following categories. Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened risk of serious bleeding. - Corticosteroids: increased likelihood of gastrointestinal ulceration. - Selective serotonin reuptake inhibitors (SSRIs): additive bleeding risk. Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal perfusion, especially in volume‑depleted patients. - Diuretics: combined effect can impair kidney function. - Lithium: ibuprofen can raise serum lithium concentrations, requiring monitoring.